MDisrupt builds Travera’s oncology advisory board
Travera is an early-stage startup, that helps oncologists speed cancer treatment decisions with their Rapid Therapy Guidance (RTG) test. Using technology developed by MIT, the test is able to evaluate a broad range of FDA-approved therapies against a patient’s cancer to determine the optimal therapy – and provide results within two days of sample collection. The test offers truly individualized guidance, derived from a patient’s unique tumor cells.
Travera wanted to rapidly assemble a high-quality group of oncology advisors to help further their growth. In particular, they wanted to move away from the traditional “celebrity” advisory board by working with practicing oncologists who could speak effectively to their peers and patients.
As an early-stage startup, Travera wanted to rapidly assemble a high-quality group of oncology advisors to help further their growth. Without a developed network of practicing oncologists, the Travera team opted to leverage the MDisrupt expert network for their product and go-to-market strategies.
Without a developed network of practicing oncologists, the Travera team opted to leverage the MDisrupt Expert Network to identify potential advisors. Within 1-month MDisrupt identified a pool of pre-vetted oncologists and performed a secondary screening to assure that candidates would meet Travera’s needs.
Travera selected 4 oncologists from the candidate pool to form the first phase of the Travera Expert Network. This group developed a deep understanding of the TraveraRTG test and uses their position to act as a bridge between Travera and their oncology peers. They use their voices to share the value of the TraveraRTG test and capture real-world feedback from other practicing oncologists that Travera uses in their product and go-to-market strategies.